Literature DB >> 7216873

Pharmacotherapeutics of the newer tetracyclines.

A L Aronson.   

Abstract

The newer tetracyclines are defined as those tetracyclines available in the United States but not approved for veterinary use. These include demeclocycline, methacycline, doxycycline, and minocycline. Of these, doxycycline and minocycline appear to offer advantages that would render them useful in certain situations in veterinary medicine. Their major advantage lies in their greater lipid solubility relative to other tetracyclines. This characteristic probably accounts for their enhanced antimicrobial effectiveness for some organisms, more efficient absorption after oral administration, and enhanced distribution in the body. The principal excretory organ for doxycycline is the intestine, where the drug diffuses through the intestinal mucosa into the intestinal tract. This unique characteristic makes this drug useful in cases of preexisting renal dysfunction and may render this drug superior to other tetracyclines in the treatment of intestinal infections. Doxycycline is used in other countries for respiratory tract and intestinal tract diseases of poultry. The usefulness of doxycycline and minocycline in food-producing animals may be limited because of persistent drug residues. Minocycline has, in large doses, been used with streptomycin in the elimination of the carrier state of canine brucellosis. The superiority of doxycycline and minocycline, relative to other tetracyclines, in their distribution to areas of he body such as the eye, brain, cerebrospinal fluid, and prostate gland suggests that trials of their efficacy in tetracycline-sensitive infections of these areas are indicated. Pharmacokinetic studies designed to determine optimal dosage schedules have not been made for domestic animals. These determinations are necessary to evaluate most effectively the usefulness of the newer tetracyclines in veterinary medicine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7216873

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  40 in total

Review 1.  Tetracyclines and pain.

Authors:  Leandro F S Bastos; Antônio C P de Oliveira; Linda R Watkins; Márcio F D Moraes; Márcio M Coelho
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-01-27       Impact factor: 3.000

2.  Minocycline Attenuates Neonatal Germinal-Matrix-Hemorrhage-Induced Neuroinflammation and Brain Edema by Activating Cannabinoid Receptor 2.

Authors:  Jun Tang; Qianwei Chen; Jing Guo; Liming Yang; Yihao Tao; Lin Li; Hongping Miao; Hua Feng; Zhi Chen; Gang Zhu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

Review 3.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

4.  Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia.

Authors:  J Yrjänheikki; R Keinänen; M Pellikka; T Hökfelt; J Koistinaho
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

5.  Experimental doxycycline overdose in rats causes cardiomyopathy.

Authors:  Mahmoud Shaban El-Neweshy
Journal:  Int J Exp Pathol       Date:  2013-02-25       Impact factor: 1.925

6.  Minocycline upregulates pro-survival genes and downregulates pro-apoptotic genes in experimental glaucoma.

Authors:  Hani Levkovitch-Verbin; Yael Waserzoog; Shelly Vander; Daria Makarovsky; Ilia Piven
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-25       Impact factor: 3.117

7.  Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.

Authors:  Liliana B Menalled; Monica Patry; Natalie Ragland; Phillip A S Lowden; Jennifer Goodman; Jennie Minnich; Benjamin Zahasky; Larry Park; Janet Leeds; David Howland; Ethan Signer; Allan J Tobin; Daniela Brunner
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

8.  In-vitro red blood cell partitioning of doxycycline.

Authors:  P V Deshmukh; P C Badgujar; M M Gatne
Journal:  Indian J Pharmacol       Date:  2009-08       Impact factor: 1.200

9.  Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2.

Authors:  Marcus Kernt; Aljoscha S Neubauer; Kirsten H Eibl; Armin Wolf; Michael W Ulbig; Anselm Kampik; Cristoph Hirneiss
Journal:  Clin Ophthalmol       Date:  2010-07-21

Review 10.  Minocycline: far beyond an antibiotic.

Authors:  N Garrido-Mesa; A Zarzuelo; J Gálvez
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.